Synlogic

Synlogic is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts. With a team of 82 employees, the company is dedicated to developing innovative treatments for serious diseases. Synlogic's focus lies in creating oral, non-systemically absorbed biotherapeutics, a novel approach to medicine. Synlogic's pipeline is centered on rare metabolic diseases, with labafenogene marselecobac (SYNB1934) leading the charge as a potential therapy for phenylketonuria (PKU). The company is also developing product candidates for other conditions such as homocystinuria (HCU), enteric hyperoxaluria, gout, and cystinuria. This diverse pipeline is powered by the Synthetic Biotic platform, which utilizes precision genetic engineering to modify well-characterized probiotics. This platform enables the creation of GI-restricted, oral medicines specifically designed to target disease-related metabolites. Synlogic's commitment to innovation is further demonstrated through its strategic collaborations. The company has partnered with Roche to explore treatments for inflammatory bowel disease (IBD) and collaborates with Ginkgo Bioworks in synthetic biology, leading to the development of two promising pipeline programs. For more information about Synlogic and its groundbreaking therapies, please visit www.synlogictx.com.